Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias

NCT02512926 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT02512926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02512926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Completed
Start date
February 16, 2016
Completion date
November 7, 2023
Enrollment
4 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

refractory leukemia, refractory solid tumors, relapsed leukemia, relapsed solid tumors